Embolization is a procedure to reduce blood flow to a tumor and prevent hemorrhaging. Obsidio’s Gel Embolic Material product line is designed to minimize embolization procedure preparation time by delivering the Gel Embolic Material through a catheter, according to the Aug. 15 Boston Scientific news release.
“The Gel Embolic Material technology combines benefits of currently available embolics, such as precise control of a solid and malleability of a liquid, to create a unique technology that offers procedural efficiency and a more personalized therapy for patients,” said Peter Pattison, president, interventional oncology and embolization, peripheral interventions at Boston Scientific. “This acquisition strengthens our interventional oncology and embolization portfolio with a differentiated solution for physicians and their patients suffering from hemorrhages, cancer and other debilitating conditions.”
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
